Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The Glaucoma in Conjunction with Cataract segment contributed the larger revenue share to the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by Product in 2017, and would continue to be a dominant market till 2024 and is expected to grow at a CAGR of 29.8% during the forecast period. However, Stand Alone Glaucoma segment is expected to grow at CAGR of 31.0% over the forecast period.
The minimally invasive glaucoma surgery (MIGS) devices market on the basis of product is segmented into MIGS stents, MIGS shunts, and other. MIGS stents segment generated the highest revenue in 2017, and is anticipated to maintain the trend throughout the forecast period. The most widely accepted stents include iStent (Glaukos Coproration), CyPass MicroStent (Alcon/Novartis), and Hydrus Microstent (Irvine) being the prime factor to drive the market growth.
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Ellex Medical Lasers Ltd, Allergan Plc, Santen Pharmaceutical Co., Ltd., Glaukos Corporation, Alcon Inc. (Novartis), Lumenis, Ivantis, Inc., iSTAR Medical, InnFocus Inc., and SOLX, Inc.
Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Segmentation
By End User
Unique Offerings from KBV Research
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Related Reports: